Aptose Biosciences Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to cash used in operating activities:
Stock-based compensation
Shares issued to Hanmi Pharmaceutical as license fees
Depreciation and amortization
Change in fair value of warrants
Depreciation of property and equipment
Loss on disposal of property and equipment
Amortization of right-of-use assets
Unrealized foreign exchange gain/(loss)
Accrued interest on investments
Noncash operating lease expense
Interest on lease liabilities
Interest on loan payable to related party

Change in operating assets and liabilities:
Prepaid expenses
Other assets
Change in operating lease liability
Accounts payable
Accounts payable, related party
Accrued liabilities, related party
Accrued liabilities
Cash used in operating activities
Cash flows from investing activities:
(Acquisition) maturity of investments, net
Maturity of investments, net
Proceeds from disposal of property and equipment
Purchase of property and equipment
Cash provided by investing activities
Effect of exchange rate fluctuations on cash and cash equivalents held

Cash flows from financing activities:
Proceeds from loan payable with related parties
Issuance of common shares and warrants
November 2024 Public Offering
January 2024 Public Offering
Hanmi Private Placement
Repayment of loan with related party
Issuance of common shares and warrants
November 2024 Public Offering
January 2024 Public Offering
Hanmi Private Placement
Offering costs paid
Issuance of common shares pursuant to exercise of stock options
Proceeds from warrant exercise
Cash provided by financing activities

Effect of exchange rate fluctuations on cash and cash equivalents
Decrease in cash, cash equivalents, restricted cash and restricted cash equivalent
Cash, cash equivalents, restricted cash and restricted cash equivalents, beginning of year
Cash, cash equivalents, restricted cash and restricted cash equivalents, end of the year
Cash and cash equivalents
Restricted cash and restricted cash equivalents

Comments